Literature DB >> 466384

Clinical pharmacological studies of amoxycillin: effect of probenecid.

R Barbhaiya, R N Thin, P Turner, J Wadsworth.   

Abstract

In a study of eight, healthy adult volunteers given 3 g amoxycillin with or without 1g probenecid, significantly higher peak plasma levels of amoxycilin were recorded in the presence (34.96 microgram/ml) of probenecid than in its absence (22.72 microgram/ml). When plasma levels were plotted against time the mean area under the curve was significantly greater for subjects given probenecid than for those given amoxycillin alone. These findings suggest that 3g amoxycillin plus 1g probenecid provide better bioavailability than 3g amoxycillin alone. The plasma levels obtained were several times higher than the minimun inhibitory concentrations (MICs) of most strains of gonococci. Plasma levels in excess of the MICs for most strains were maintained for eight hours with both regimens, but the higher levels in the presence of probenecid support the better clinical results previously reported with this regimen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466384      PMCID: PMC1045632          DOI: 10.1136/sti.55.3.211

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  8 in total

1.  Triple crossover study on absorption and excretion of ampicillin, pivampicillin, and amoxycillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations.

Authors:  J M BURNELL; W M M KIRBY
Journal:  J Clin Invest       Date:  1951-07       Impact factor: 14.808

3.  A simple, rapid fluorimetric assay of amoxycillin in plasma.

Authors:  R H Barbhaiya; P Turner; E Shaw
Journal:  Clin Chim Acta       Date:  1977-06-15       Impact factor: 3.786

4.  Oral ampicillin in uncomplicated gonorrhoea. IV. Comparison of pharmacological and clinical results.

Authors:  G Eriksson
Journal:  Acta Derm Venereol       Date:  1971       Impact factor: 4.437

5.  A double trial of amoxycillin in the treatment of gonorrhoea.

Authors:  R N Thin; M A Symonds; E J Shaw; J Wong; P K Hopper; B Slocombe
Journal:  Br J Vener Dis       Date:  1977-04

6.  Comparative clinical pharmacology of amoxicillin and ampicillin administered orally.

Authors:  C Gordon; C Regamey; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1972-06       Impact factor: 5.191

7.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  Amoxycillin: a new semi-synthetic penicillin.

Authors:  R Sutherland; E A Croydon; G N Rolinson
Journal:  Br Med J       Date:  1972-07-01
  8 in total
  5 in total

1.  Proceedings of the British Thoracic Society, Scottish Thoracic Society and Thoracic Society of Australia. The 1987 summer meeting. 1-3 July, Edinburgh. Abstracts.

Authors: 
Journal:  Thorax       Date:  1987-09       Impact factor: 9.139

2.  Effect of probenecid on amoxycillin.

Authors:  K Woodcock
Journal:  Br J Vener Dis       Date:  1980-06

Review 3.  Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

Authors:  D Kunimoto; R Brunham; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

4.  High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.

Authors:  Xue Yang; Jin-Xia Wang; Sheng-Xi Han; Cai-Ping Gao
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

5.  Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.

Authors:  Wen Gao; Guigen Teng; Chi Wang; Ying Xu; Yixuan Li; Hong Cheng
Journal:  Helicobacter       Date:  2022-07-25       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.